WAR-LOCK
LIVE

Serial Number

97716183

Owner

Enlaza Therapeutics, Inc.

Attorney

Alyssa M Worsham

Filing Date

Dec 13, 2022

Add to watchlist:

No watchlists yet
View on USPTO

WAR-LOCK Trademark

Serial Number: 97716183

WAR-LOCK is a trademark filed by Enlaza Therapeutics, Inc. on December 13, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Enlaza Therapeutics, Inc. (3 trademarks)

11099 North Torrey Pines Road, Suite 280
La Jolla, CA 92037

Entity Type: 03

Trademark Details

Filing Date

December 13, 2022

Registration Date

Not Registered

Published for Opposition

January 16, 2024

Goods & Services

Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, testing in the field of recombinant protein production and bioconjugation; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies

Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products, namely, covalent protein drugs for the treatment of cancer diseases; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products consisting of covalent protein drugs for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals

Chemicals for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research, namely, for therapeutic drug development; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use, namely, for therapeutic drug development

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 31, 2026 EXRA
SOU EXTENSION 4 GRANTED
Jan 30, 2026 EX4G
SOU EXTENSION 4 FILED
Jan 30, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 30, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 25, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jul 24, 2025 EX3G
SOU EXTENSION 3 FILED
Jul 24, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 5, 2025 EXRA
SOU EXTENSION 2 GRANTED
Mar 5, 2025 EX2G
SOU EXTENSION 2 FILED
Mar 4, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 4, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 15, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 15, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 15, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 15, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 12, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 16, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 16, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 27, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 7, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 7, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 7, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 7, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 7, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 29, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 28, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 28, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 22, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 22, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 22, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 16, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 10, 2023 NWOS
NEW APPLICATION ENTERED
Dec 16, 2022 NWAP